Mineralys Therapeutics (MLYS) Common Equity (2022 - 2026)
Quarterly results put Common Equity at $638.1 million for Q1 2026, up 86.83% from a year ago — trailing twelve months through Mar 2026 was $638.1 million (up 86.83% YoY), and the annual figure for FY2025 was $646.7 million, up 238.13%.
Mineralys Therapeutics has reported Common Equity over the past 5 years, most recently at $638.1 million for Q1 2026.
- Common Equity reached $638.1 million in Q1 2026 per MLYS's latest filing, down from $646.7 million in the prior quarter.
- Across five years, Common Equity topped out at $646.7 million in Q4 2025 and bottomed at -$52.3 million in Q4 2022.
- Median Common Equity over the past 5 years was $285.0 million (2023), compared with a mean of $263.9 million.
- The largest annual shift saw Common Equity soared 1070.88% in 2023 before it decreased 20.69% in 2024.
- Over 5 years, Common Equity stood at -$52.3 million in 2022, then soared by 561.37% to $241.2 million in 2023, then dropped by 20.69% to $191.3 million in 2024, then soared by 238.13% to $646.7 million in 2025, then dropped by 1.32% to $638.1 million in 2026.
- Business Quant data shows Common Equity for MLYS at $638.1 million in Q1 2026, $646.7 million in Q4 2025, and $576.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 31.42 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 13.21 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Mineralys Therapeutics | 2.50 Bn | 2.50 Bn | - | 638.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 638.14 Mn |
| Dec 31, 2025 | 646.69 Mn |
| Sep 30, 2025 | 576.43 Mn |
| Jun 30, 2025 | 313.55 Mn |
| Mar 31, 2025 | 341.56 Mn |
| Dec 31, 2024 | 191.26 Mn |
| Sep 30, 2024 | 236.93 Mn |
| Jun 30, 2024 | 290.10 Mn |
| Mar 31, 2024 | 328.05 Mn |
| Dec 31, 2023 | 241.15 Mn |
| Sep 30, 2023 | 264.01 Mn |
| Jun 30, 2023 | 285.01 Mn |
| Mar 31, 2023 | 295.88 Mn |
| Dec 31, 2022 | -52.27 Mn |
| Sep 30, 2022 | -43.41 Mn |
| Jun 30, 2022 | -36.93 Mn |
| Mar 31, 2022 | -30.48 Mn |